Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan OTC ticker: 1795) today announced that MA of the branded product AclastaR solution for infusion was successfully transferred from Novartis Taiwan to Lotus Pharmaceutical. The acquired product for osteoporosis will be marketed in Taiwan by Lotus.
LOTUS WILL MARKET ACLASTA IN TAIWAN: LOTUS GENERAL MANAGER JEFFERSON WANG AND DR. RONG-SEN YANG FROM DEPARTMENT OF ORTHOPEDIC SURGERY OF NATIONAL TAIWAN UNIVERSITY HOSPITAL EXCHANGED THOUGHTS ON THE THERAPEUTIC AREA
The acquisition of this well-established branded product further strengths Lotus’ branded portfolio in Taiwan particularly in a steadily growing market as osteoporosis. Commenting on the transaction, Jefferson Wang, General Manager of Lotus, said, “The acquisition solidifies our local portfolio and enhances our platform for continued growth across the APAC region. We continue to build our offer in Taiwan to catalyze growth and there will be more new product launches starting 2017.”